This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Growth hormone therapy

Authoring team

Synthetic human growth hormone is licensed in the UK for the treatment of children with growth hormone deficiency, and children with short stature associated with chronic renal insufficiency (renal function decreased to less than 50%), Turner's syndrome (gonadal dysgenesis) and Prader-Willi syndrome. Synthetic growth hormone is also licensed (in the UK) for use in adults with growth hormone deficiency.

  • companies recommend that treatment with synthetic growth hormone "should be initiated and monitored by physicians..experienced in the diagnosis and management of growth disorders"
  • synthetic growth hormone is administered daily by subcutaneous injection - it is best administered in the evening to mimic the normal physiological nocturnal increase in secretion of growth hormone
  • the best way to monitor response to treatment is via calculations of height velocity and interval height increase. It is also possible to monitor progress via measurement of serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3

Reference: (1) Drugs and Therapeutics Bulletin (2002), 40 (3), 17-20.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.